Session XIX: Presentation of Selected Abstracts on GI Cancer

Presentation during WCGIC:

All abstracts will be published on the Annals of Oncology website on Saturday, 02 July at 16:30 CEST.

Abstract titles and summaries were obtained from the ESMO WCGIC website; abstracts were translated, edited, and summarized in German.

------------------------------------------------------------------------------------------------------------------------------------------

SO-31: Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

E. Garralda, et l.

------------------------------------------------------------------------------------------------------------------------------------------

SO-32: Entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

I. Garrido-Laguna, et al.

https://doi.org/10.1016/j.annonc.2022.04.431

------------------------------------------------------------------------------------------------------------------------------------------

SO-33: Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

S. Chakrabarti, et al.

------------------------------------------------------------------------------------------------------------------------------------------

LBA SO-34: Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations

in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

M. Salem, et al.

------------------------------------------------------------------------------------------------------------------------------------------

 

SO-35: T-cell abundance measured by immunoSEQ predicts overall survival in colorectal cancer

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

S. Gruber, et al.

------------------------------------------------------------------------------------------------------------------------------------------

SO-36: An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer:

a translational analysis of the phase II randomized AtezoTRIBE study

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

C. Antoniotti, et al.

https://doi.org/10.1016/j.annonc.2022.04.434

------------------------------------------------------------------------------------------------------------------------------------------

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close